---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-23-000074"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T14:14:13.532473+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Allogene reports Q2 2023 net loss of $78.0M; cash extends into 2H 2025

## Summary
- Cash, equivalents, and investments $544.5M as of June 30, 2023; raised $87.9M via ATM in Q2.
- Net loss $78.0M ($0.53/share) including $16.6M non-cash stock-based comp.
- ALLO-501A Phase 2 ALPHA2 enrollment expected to complete 1H 2024; data readout by year-end 2024.
- Long-term data from ALPHA/ALPHA2 trials showed complete response rates similar to approved autologous CAR T.
- Cash runway now projected into 2H 2025; 2023 operating expense guidance ~$340M.

## SEC filing metadata
- accession: 0001737287-23-000074
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000074/0001737287-23-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000074/allo-20230802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-23-000074
- JSON: https://secwatch.observer/filing/0001737287-23-000074.json
- Plain text: https://secwatch.observer/filing/0001737287-23-000074.txt

## Key facts
- Earnings Releases
  Allogene Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 2, 2023, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended June 30, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000074/0001737287-23-000074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.